Block GA, et al. - Among patients with advanced CKD, researchers focused on the impact of a fixed-dose ferric citrate coordination complex on various biochemical parameters. Via random assignment 2:1, a fixed dose of ferric citrate coordination complex (two tablets per meal, 210 mg ferric iron per tablet) or usual care was given to 203 patients with eGFR≤20 ml/min per 1.73 m² for 9 months or until 3 months after commencing dialysis. Significant rise in hemoglobin, transferrin saturation, and serum ferritin, and a significant decrease in serum phosphate and intact fibroblast growth factor 23 was found in relation to treatment with ferric citrate coordination complex. Findings also revealed significantly fewer annualized hospital admissions, fewer days in hospital, and a lower incidence of the composite end point of death, provision of dialysis, or transplantation in relation to ferric citrate coordination complex treatment vs usual care. In this study, an excellent safety profile of fixed-dose ferric citrate coordination complex in an unselected population with advanced CKD was indicated by the observed beneficial impacts of fixed-dose ferric citrate coordination complex on biochemical parameters, as well as the exploratory outcomes about the composite end point and hospitalization.